Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
-
- Eri T. Kato
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Japan (E.T.K.).
-
- Michael G. Silverman
- Cardiology Division, Massachusetts General Hospital, Boston (M.G.S.).
-
- Ofri Mosenzon
- Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel (O.M., A.C., I.R.).
-
- Thomas A. Zelniker
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (T.A.Z., R.H.M.F., J.K., S.A.M., D.L.B., C.T.R., M.S.S., S.D.W.).
-
- Avivit Cahn
- Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel (O.M., A.C., I.R.).
-
- Remo H.M. Furtado
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (T.A.Z., R.H.M.F., J.K., S.A.M., D.L.B., C.T.R., M.S.S., S.D.W.).
-
- Julia Kuder
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (T.A.Z., R.H.M.F., J.K., S.A.M., D.L.B., C.T.R., M.S.S., S.D.W.).
-
- Sabina A. Murphy
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (T.A.Z., R.H.M.F., J.K., S.A.M., D.L.B., C.T.R., M.S.S., S.D.W.).
-
- Deepak L. Bhatt
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (T.A.Z., R.H.M.F., J.K., S.A.M., D.L.B., C.T.R., M.S.S., S.D.W.).
-
- Lawrence A. Leiter
- Li Ka Shing Knowledge Institute, St. Michael’s Hospital, University of Toronto, Ontario, Canada (L.A.L.).
-
- Darren K. McGuire
- Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (D.K.M.).
-
- John P.H. Wilding
- Institute of Ageing and Chronic Disease, University of Liverpool, UK (J.P.H.W.).
-
- Marc P. Bonaca
- CPC Clinical Research, University of Colorado, Denver (M.P.B.).
-
- Christian T. Ruff
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (T.A.Z., R.H.M.F., J.K., S.A.M., D.L.B., C.T.R., M.S.S., S.D.W.).
-
- Akshay S. Desai
- Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (A.S.D.).
-
- Shinya Goto
- Department of Medicine (Cardiology), Tokai University, Isehara, Japan (S.G.).
-
- Peter A. Johansson
- AstraZeneca, Gothenburg, Sweden (P.A.J., I.G.-N., P.J., A.M.L.).
-
- Ingrid Gause-Nilsson
- AstraZeneca, Gothenburg, Sweden (P.A.J., I.G.-N., P.J., A.M.L.).
-
- Per Johanson
- AstraZeneca, Gothenburg, Sweden (P.A.J., I.G.-N., P.J., A.M.L.).
-
- Anna Maria Langkilde
- AstraZeneca, Gothenburg, Sweden (P.A.J., I.G.-N., P.J., A.M.L.).
-
- Itamar Raz
- Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel (O.M., A.C., I.R.).
-
- Marc S. Sabatine
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (T.A.Z., R.H.M.F., J.K., S.A.M., D.L.B., C.T.R., M.S.S., S.D.W.).
-
- Stephen D. Wiviott
- TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA (T.A.Z., R.H.M.F., J.K., S.A.M., D.L.B., C.T.R., M.S.S., S.D.W.).
抄録
<jats:sec> <jats:title>Background:</jats:title> <jats:p>In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) on the clinical benefit of sodium-glucose cotransporter 2 inhibition is unknown.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>In the DECLARE-TIMI 58 trial, baseline heart failure (HF) status was collected from all patients, and EF was collected when available. HF with reduced EF (HFrEF) was defined as EF <45%. Outcomes of interest were the composite of cardiovascular death/HHF, its components, and all-cause mortality.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p> Of 17 160 patients, 671 (3.9%) had HFrEF, 1316 (7.7%) had HF without known reduced EF, and 15 173 (88.4%) had no history of HF at baseline. Dapagliflozin reduced cardiovascular death/HHF more in patients with HFrEF (hazard ratio [HR], 0.62 [95% CI, 0.45–0.86]) than in those without HFrEF (HR, 0.88 [95% CI, 0.76–1.02]; <jats:italic>P</jats:italic> for interaction=0.046), in whom the treatment effect of dapagliflozin was similar in those with HF without known reduced EF (HR, 0.88 [95% CI, 0.66–1.17]) and those without HF (HR, 0.88 [95% CI, 0.74–1.03]). Whereas dapagliflozin reduced HHF both in those with (HR, 0.64 [95% CI, 0.43–0.95]) and in those without HFrEF (HR, 0.76 [95% CI, 0.62–0.92]), it reduced cardiovascular death only in patients with HFrEF (HR, 0.55 [95% CI, 0.34–0.90]) but not in those without HFrEF (HR, 1.08 [95% CI, 0.89–1.31]; <jats:italic>P</jats:italic> for interaction=0.012). Likewise, dapagliflozin reduced all-cause mortality in patients with HFrEF (HR, 0.59 [95% CI, 0.40–0.88;) but not in those without HFrEF (HR, 0.97 [95% CI, 0.86–1.10]; <jats:italic>P</jats:italic> for interaction=0.016). </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>In the first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, we found that dapagliflozin reduced HHF in patients with and without HFrEF and reduced cardiovascular death and all-cause mortality in patients with HFrEF.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical Trial Registration:</jats:title> <jats:p> URL: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</jats:ext-link> . Unique identifier: NCT01730534. </jats:p> </jats:sec>
収録刊行物
-
- Circulation
-
Circulation 139 (22), 2528-2536, 2019-05-28
Ovid Technologies (Wolters Kluwer Health)
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360285711411997568
-
- ISSN
- 15244539
- 00097322
-
- データソース種別
-
- Crossref
- KAKEN